Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingPSNL
PSNL▼
Personalis falls on downgrade as competing bid seen unlikely
Personalis Inc. dropped 6% after Craig-Hallum downgraded the cancer test maker to hold from buy, saying a higher bid than its announced sale to Tempus AI is unlikely. Tempus shares fell 7.2%. Last month, Tempus AI agreed to buy Personalis for $16.25 a share in a primarily all-stock deal, with Tempus having the option to pay up to 50% in cash. Craig-Hallum analyst Bill Bonello wrote that a competing bid is unlikely because Tempus is the key commercial partner responsible for selling Personalis's NeXT Personal MRD Test, and Merck, which owns about 13% of Personalis shares, has agreed to vote in favor of the deal with Tempus.
Tempus AI Legal Chief Sells $1.5 Million in Shares
Tempus AI's chief legal officer Andrew Polovin sold 30,075 shares at $51.29 per share in a transaction totaling $1.5 million, according to an SEC filing. The sale was non-discretionary, executed to cover minimum statutory tax withholding obligations tied to the vesting of restricted stock units, and was conducted under a Rule 10b5-1 trading plan established on August 12, 2025. Following the disposition, Polovin retains 138,140 shares with an estimated market value of $8.5 million as of the August 19 close. Tempus AI shares have rallied about 75% since late last month, driven partly by a Moderna and Merck cancer vaccine trial hitting its endpoints, which validates the genomic sequencing technology behind Tempus's pending $1.5 billion Personalis deal. The company reported revenue up 22% to $382.5 million last quarter and its first GAAP profit.
Tempus AI Surges 39.5% on mRNA Melanoma Trial Win and Personalis Deal
Tempus AI shares jumped 39.5% after phase 3 INTerpath-001 trial results showed a customized mRNA-based melanoma treatment improved recurrence-free survival, alongside its pending US$1.50 billion acquisition of Personalis Inc. The trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. The Personalis deal would deepen Tempus AI's role in cancer genomics at the same time customized mRNA oncology approaches show clinical success, potentially strengthening the case that its data assets, assays, and AI tools are becoming more embedded in cutting edge oncology programs. Tempus AI's narrative projects $2.6 billion revenue and $13.4 million earnings by 2029, requiring 22.0% yearly revenue growth and roughly a $268 million earnings increase from -$254.4 million today. Some of the most optimistic analysts were already assuming revenue could reach about US$2.7 billion and earnings turn positive by 2029, and this new oncology trial result might eventually push those views even further apart.
Wohl & Fruchter Investigates Fairness of Personalis Sale to Tempus AI
The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis to Tempus AI for $16.25 per share. The consideration will be a mix of Tempus common stock and up to 50% cash, with a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share. Since the deal was announced on July 20, 2026, Tempus shares have dropped from $52.47 to $46.05, and Personalis shares have fallen about 14% from $15.39 to $13.20. Some Personalis stockholders have voiced disappointment on SeekingAlpha. The firm is examining whether the Personalis board acted in shareholders' best interests and whether all material information was disclosed.
Tempus AI Returns to Profit, Raises 2026 Revenue Outlook, and Plans Personalis Acquisition
Tempus AI reported second-quarter 2026 net income of US$5.64 million, swinging from a net loss of US$42.84 million a year ago, while revenue reached US$382.49 million. The company raised its full-year 2026 revenue guidance to between US$1.60 billion and US$1.61 billion. Tempus AI also announced a planned acquisition of Personalis to add cancer recurrence monitoring technology to its oncology and data platform. The return to profitability and higher outlook support the growth narrative, though risks around reimbursement and biopharma budgets remain.
Tempus AI CEO Eric Lefkofsky Sold 250,000 Shares Under a Pre-Scheduled Trading Plan
Tempus AI CEO and Chairman Eric P. Lefkofsky sold 250,000 shares of Class A Common Stock on July 28, 2026, in a transaction valued at $10.5 million. The sale was executed under a Rule 10b5-1 trading plan established in March 2026, indicating it was part of routine portfolio management rather than a reaction to market conditions. Following the transaction, Lefkofsky retains approximately 6.5 million shares across direct and indirect holdings, valued at $279.52 million based on the July 28 closing price of $42.90, representing a roughly 4% reduction in his total stake. The company, which operates a healthcare technology platform integrating clinical software, laboratory diagnostics, and AI-driven analytics, reported second-quarter 2026 revenue growth of 20% year over year and recently announced a $1.5 billion agreement to acquire Personalis.
Halper Sadeh LLC Investigates Finward Bancorp and Personalis Sales for Shareholder Fairness
Halper Sadeh LLC, an investor rights law firm, is investigating Finward Bancorp and Personalis, Inc. over their proposed sales, questioning whether shareholders are receiving fair deals. The firm is examining Finward Bancorp's sale to First Financial Bancorp, where each Finward share would be exchanged for 1.35 shares of First Financial common stock, and Personalis, Inc.'s sale to Tempus AI, Inc. for $16.25 per share. Halper Sadeh LLC suggests that insiders may obtain substantial financial benefits not available to ordinary shareholders and that the proposed transactions may contain terms limiting superior competing offers. The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, and encourages affected investors to contact them to discuss their rights at no cost or obligation.
Brodsky & Smith investigates boards of Luxfer, Finward, Personalis, and Distribution Solutions over merger fairness
Brodsky & Smith is investigating the boards of Luxfer Holdings, Finward Bancorp, Personalis, and Distribution Solutions Group for potential fiduciary duty breaches in their respective merger agreements. Luxfer Holdings is being acquired by Wynnchurch Capital for $17.37 per share in cash. Finward Bancorp is being acquired by First Financial Bancorp in an all-stock deal valued at approximately $208 million, with each Finward share converting into 1.35 First Financial shares. Personalis is being acquired by Tempus AI for $16.25 per share, representing a total enterprise value of $1.5 billion net of Tempus’ existing ownership. Distribution Solutions Group is being acquired by LKCM Headwater Investments for $35.00 per share in cash, with LKCM Headwater and its affiliates already owning approximately 79% of the company’s outstanding common stock and the company’s Chairman and CEO serving as Managing Partner of LKCM Headwater. The investigations focus on whether the boards failed to conduct a fair process and secure fair value for shareholders.
Tempus AI to acquire Personalis in $1.5 billion all-stock deal
Tempus AI has agreed to acquire cancer testing company Personalis in a roughly $1.5 billion all-stock deal, aiming to integrate Personalis' minimal residual disease testing into its precision oncology and data platform. The combined entity would target a cancer monitoring market estimated at around $20 billion, with the deal expected to close by late 2026 or early 2027. Tempus AI's share price has fallen 21.46% year to date and dropped 16.52% in the seven days around the announcement, suggesting investors are reassessing growth potential and deal-related risks. While one narrative sees the stock as undervalued with a fair value of $65.90 compared to its last close of $48.98, its current price-to-sales ratio of 6.4 times exceeds the US Life Sciences industry average of 3.9 times and peer levels of 5 times, though it remains below a fair ratio of 7.8 times.
Brodsky & Smith investigates boards of five companies over merger fairness
Brodsky & Smith is investigating the boards of Personalis, Distribution Solutions Group, Cross Country Healthcare, Nuvalent, and Dana Incorporated for potential fiduciary duty breaches in connection with their proposed acquisitions. Personalis is being acquired by Tempus AI for $16.25 per share, representing a total enterprise value of $1.5 billion net of Tempus’ existing ownership. Distribution Solutions Group is being acquired by LKCM Headwater Investments for $35.00 per share in cash, with LKCM Headwater and its affiliates already owning approximately 79% of the company’s outstanding common stock. Cross Country Healthcare is being acquired by Knox Lane for $13.25 per share in an all-cash transaction valued at $437 million. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company at close, and Eaton will receive a cash distribution of approximately $1.1 billion. The investigations focus on whether the boards failed to conduct a fair process and whether the proposed transactions pay fair value to shareholders.
Julie & Holleman Investigates Personalis Sale to Tempus
Julie & Holleman LLP is investigating the proposed acquisition of Personalis by Tempus AI. The deal values Personalis at $16.25 per share. The law firm is concerned that Tempus' existing equity stake and strategic partnership with Personalis may have created conflicts of interest during the sale process. Julie & Holleman is evaluating whether the merger consideration fairly reflects Personalis' long-term value in the growing molecular residual disease testing market.